TY - JOUR
T1 - Postoperative 5-FU based Radiochemotherapy in Rectal Cancer
T2 - Retrospective Long Term Results and Prognostic Factors of a Pooled Analysis on 1,338 Patients
AU - Genovesi, Domenico
AU - Myerson, Robert J.
AU - Cèfaro, Giampiero Ausili
AU - Vinciguerra, Annamaria
AU - Augurio, Antonietta
AU - Trignani, Marianna
AU - Di Tommaso, Monica
AU - Nuzzo, Marianna
AU - Lupattelli, Marco
AU - Aristei, Cynthia
AU - Bellavita, Rita
AU - Scandolaro, Luciano
AU - Cosentino, Dorian
AU - Pani, Giuseppe
AU - Ziccarelli, Luigi
AU - Gambacorta, Maria A.
AU - Barba, Maria C.
AU - Maranzano, Ernesto
AU - Trippa, Fabio
AU - Sciacero, Piera
AU - Niespolo, Rita
AU - Leonardi, Cristina
AU - Iannone, Tiziana
AU - Rosetto, Maria Elena
AU - Fusco, Vincenzo
AU - Sanpaolo, Piero
AU - Melano, Antonella
AU - Valvo, Francesca
AU - Capirci, Carlo
AU - De Paoli, Antonino
AU - Di Nicola, Marta
AU - Mantello, Giovanna
AU - Valentini, Vincenzo
PY - 2013/10
Y1 - 2013/10
N2 - Aim: To evaluate survival outcomes of patients in pStage II-III rectal cancer treated with adjuvant 5-fluorouracil-based radiochemotherapy and toretrospectively analyzethe impact of prognostic variables on local control, metastasis-free survival and cause-specific survival. Patients and Methods: A total of 1,338 patients, treated between 1985-2005 for locally advanced rectal cancer, who underwent surgery and postoperative 5-fluorouracil-based chemoradiation, were selected. Results: The actuarial 5- and 10-year outcomes were: local control 87.0%-84.1%, disease-free survival 61.6%-52.1%, metastasis-free survival 72.0%-67.2%, cause-specific survival 70.4%-57.5%, and overall survival 63.8%-53.4%. Better outcomes were observed in patients with IIA, IIIA stage. Multivariate analyses showed that variables significantly affecting metastasis-free survival were pT4 and pN2, while for cancer-specific survival those variables were age >65 years, pT4, pN1, pN2, distal tumors and number of lymph nodes removed ≤12. Conclusion: This study confirmed that among stage II-III rectal cancer patients there are subgroups of patients with different clinical outcomes.
AB - Aim: To evaluate survival outcomes of patients in pStage II-III rectal cancer treated with adjuvant 5-fluorouracil-based radiochemotherapy and toretrospectively analyzethe impact of prognostic variables on local control, metastasis-free survival and cause-specific survival. Patients and Methods: A total of 1,338 patients, treated between 1985-2005 for locally advanced rectal cancer, who underwent surgery and postoperative 5-fluorouracil-based chemoradiation, were selected. Results: The actuarial 5- and 10-year outcomes were: local control 87.0%-84.1%, disease-free survival 61.6%-52.1%, metastasis-free survival 72.0%-67.2%, cause-specific survival 70.4%-57.5%, and overall survival 63.8%-53.4%. Better outcomes were observed in patients with IIA, IIIA stage. Multivariate analyses showed that variables significantly affecting metastasis-free survival were pT4 and pN2, while for cancer-specific survival those variables were age >65 years, pT4, pN1, pN2, distal tumors and number of lymph nodes removed ≤12. Conclusion: This study confirmed that among stage II-III rectal cancer patients there are subgroups of patients with different clinical outcomes.
KW - Adjuvant therapy
KW - Prognostic factors
KW - Rectal cancer
KW - Staging
UR - http://www.scopus.com/inward/record.url?scp=84891367967&partnerID=8YFLogxK
M3 - Article
C2 - 24123031
AN - SCOPUS:84891367967
SN - 0250-7005
VL - 33
SP - 4557
EP - 4566
JO - Anticancer Research
JF - Anticancer Research
IS - 10
ER -